Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Takeda Oncology.
Expert Illustrations & Commentaries™: Reshaping the Clinical Landscape of HR-MDS Through Novel Mechanisms of Action
Release Date: October 15, 2021
Expiration Date: October 15, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Takeda Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Illustrate the underlying mechanisms of oncogenic signaling and immune escape in MDS and the rationale for targeting these pathways in the treatment of higher-risk MDS
- Evaluate efficacy and safety profiles of emerging agents/combinations in patients with higher-risk MDS
- Implement strategies to monitor and manage toxicities associated with therapeutic approaches in higher-risk MDS
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities
Faculty

Director, Bone Marrow Failure and MDS Program
Associate Professor of Oncology
Associate Professor of Medicine
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, MD
Disclosures: Other Support: Taiho, Takeda, Bristol Myers Squibb, Novartis, AbbVie.

Chief, Division of Hematology
Professor of Medicine
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Miami, FL
Disclosures: Other Support: Advisory Board: Bristol Myers Squibb, Novartis, Takeda, Millennium.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.